|Bid||3.0200 x 29200|
|Ask||3.7400 x 800|
|Day's Range||3.1200 - 3.3000|
|52 Week Range||3.0100 - 18.5000|
|Beta (3Y Monthly)||2.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.65|
Investors love a turnaround play, and Wall Street is littered with stories of fortunes made betting on troubled companies.In the 1960s, American Express (AXP) was rumored to be near bankruptcy when Warren Buffett famously entered what is now one of his favorite Berkshire Hathaway positions. Apple (AAPL), which became the first U.S. company to hit $1 trillion in market value, absorbed more than a decade of losses during the 1980s and '90s before Steve Jobs helped turn the company around - aided by a $150 million investment from Microsoft (MSFT).But while every beat-up stock is a potential turnaround play, not every company achieves that potential. And losses can mount quickly for a stock that's already up against the ropes. So while you might be tempted to dabble in a potential comeback story or two, beware of some of the most common traps that end in disaster.Sometimes the issue is too much debt; rising interest costs and balloon payments can turn minor business setbacks into major liquidity challenges. Other times, once-powerful consumer brands are brought to their knees by management that's too slow to adapt to evolving consumer tastes.Certain areas of the market can be particularly prone to disasters. Start-up biotech stocks are risky because they're racing against the clock to bring new drugs to market before their cash runs out. Disappointing clinical trial result, in these cases, can cut a stock's value in half (or worse) within days. Chinese stocks are problematic, too, because of sometimes poor visibility and weak corporate governance.Here are 13 stocks to sell if you own them, or avoid if you're on the hunt for the next turnaround story. The companies themselves aren't necessarily an extinction threat, but for varying reasons, they're all on the brink of delivering more disastrous returns. SEE ALSO: Beware the Risks in These 13 Blue-Chip Stocks
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.
Teva Pharmaceuticals (NYSE:TEVA) is having a Monday of nightmares as some of the company's products have led to lawsuits, which brought about a major analyst downgrade, causing TEVA stock to plummet early in the week.Source: Shutterstock The Israel-based pharma business with a global reach suffered today as the company's opioid-linked litigation has only started to kick off, with thousands of new lawsuits on the horizon. The harmful painkillers recently led to a judge giving the green light for an $85 million settlement in the state of Oklahoma, ensuring that the company will not promote opioids in the state.This is only the tip of the iceberg for Teva, which had a Monday that saw Morgan Stanley lower the stock's rating from an Equal Weight to an Underweight. The firm added that its price target on TEVA stock has now decreased from $16 per share to $6 per share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMorgan Stanley analyst David Risinger noted that the pharmaceutical giant, as well as competitors such as Endo International PLC (NASDAQ:ENDP), are experiencing "underappreciated risks" coming from buying group pressure, which are now more negative than predicted.These include a rise in generic competition, as well as the aforementioned opioid-related suits. The note arrived soon after Argus Capital upped its rating on TEVA stock to a buy with a $12 price target on July 5, 2019.TEVA stock fell 7.5% by day's end, while ENDO stock slid 3.7%. More From InvestorPlace * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond * 7 Dependable Dividend Stocks to Buy * 7 Retail Stocks to Buy for the Second Half of 2019 * 10 Stocks to Sell for an Economic Slowdown The post Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today appeared first on InvestorPlace.
Teva Pharmaceutical shares moved lower after Morgan Stanley downgraded the stock to Underweight with a price target of $6 per share.
Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...
In a report midday Monday, RBC Capital Markets analyst Randall Stanicky wrote that he did not believe that the loan, which came from an existing revolving credit facility, was taken to pay a potential opioid settlement.
Moody's Investors Service ("Moody's") downgraded the ratings of Endo Luxembourg Finance I Company S.à.r.l., and other subsidiaries of Endo International plc (together, "Endo"). The Corporate Family Rating was downgraded to B3 from B2 and the Probability of Default Rating was downgraded to B3-PD from B2-PD.
(Bloomberg) -- AbbVie Inc.’s deal to buy Botox maker Allergan Plc for $63 billion is reviving excitement on Wall Street for makers of specialty and generic drugs, at least for today.For now, investors are shrugging off concerns surrounding the opioid crisis and highly leveraged balance sheets to rush back to drugmakers ranging from flailing Teva Pharmaceutical Industries Ltd. to Endo International Plc in the aftermath of AbbVie’s deal as they position for the next multi-billion dollar deal.Shares of drugmakers jumped early Tuesday, led by a 4.7% advance for Endo and a 3.2% gain for Teva. Peers like Mallinckrodt Plc, Mylan NV, Bausch Health Co, Perrigo Co., and Jazz Pharmaceuticals Plc traded higher as the market saw small losses.The relief rally couldn’t be better timed for an industry that has seen share prices crater to five- to 20-year lows across the board as concerns from opioid liability to sinking generic drug prices and pressures from the White House pushed investors to the exits. But with valuation being the main driver for potential investor interest, Barclays analyst Balaji Prasad advised investors to “resist the temptation” in a note earlier this month.The announcement split Wall Street analysts with Cantor analyst Louise Chen saying the deal brings Perrigo into light as a potential target “given their move toward pureplay consumer and an activist shareholder in the stock.” While Citi’s Andrew Baum disagreed, calling the deal more AbbVie specific “rather than heralding a broader wave of large cap M&A across the sector.”It’s worth noting that the large cap-skewed Nasdaq Biotechnology exchange-traded fund, (IBB), rose 0.9% after the open, while the equal-weighted SPDR S&P Biotech ETF (XBI) gained close to 1% in a sign that investors are expecting a further uptick in deal volume for the blossoming biotech sector. Biogen Inc. -- one of the drugmakers that investors now think may fit the profile of a company looking for a rescue -- outperformed, climbing 4%.(Updates share movement in third paragraph, adds analyst commentary in final paragraph.)To contact the reporter on this story: Bailey Lipschultz in New York at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.
Paul Campanelli became the CEO of Endo International plc (NASDAQ:ENDP) in 2016. This report will, first, examine the...
In 2016 Paul Campanelli was appointed CEO of Endo International plc (NASDAQ:ENDP). This report will, first, examine...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
BRIDGEWATER, N.J. and RALEIGH, N.C., June 18, 2019 -- Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic.
Endo International PLC NASDAQ/NGS:ENDPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ENDP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $9.50 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal. Endo Pharmaceuticals and Dr. Spitz encourage men to conduct self-penile exams to look for a curvature and feel for a lump this June, which is Men's Health Month.